Here are three key points:
1. The Congressional Budget Office estimated this tax suspension could save the companies about $5 billion.
2. The tax didn’t impact employment much, according to the Congressional Research Service. However, the report also concluded the tax didn’t seem necessary or beneficial.
3. Jason McGorman of Bloomberg Intelligence noted the tax suspension will help large medical device companies’ bottom lines.
More articles on devices:
Nanotherapeutics grants worldwide license to Amend Surgical for bone void filler: 5 notes
Moody’s: 3 important insights into the orthopedic device industry in 2016
MiMedx buys Stability Biologics — 5 takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
